HTLV-1 seropositive patients with lung cancer treated with PD-1 inhibitors

Cancer Sci. 2020 Sep;111(9):3395-3396. doi: 10.1111/cas.14536. Epub 2020 Jul 18.

Affiliations

¹ Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
² Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
³ Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / adverse effects
Antineoplastic Agents, Immunological / adverse effects*
Asymptomatic Infections
Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Non-Small-Cell Lung / immunology
Carrier State / blood
Carrier State / diagnosis*
Carrier State / immunology
Carrier State / virology
Follow-Up Studies
HTLV-I Antibodies / blood
HTLV-I Antibodies / immunology
HTLV-I Infections / chemically induced
HTLV-I Infections / diagnosis*
HTLV-I Infections / immunology
HTLV-I Infections / virology
Human T-lymphotropic virus 1 / immunology*
Human T-lymphotropic virus 1 / isolation & purification
Humans
Lung Neoplasms / drug therapy
Lung Neoplasms / immunology
Male
Middle Aged
Nivolumab / adverse effects
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Programmed Cell Death 1 Receptor / immunology
Retrospective Studies

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
HTLV-I Antibodies
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Nivolumab
pembrolizumab